Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 4/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236109 | 1.00 | EEF2K (0.47) | EEF2KGAAKMT2AMEN1CNR2 | |
| SCHEMBL2457680 | 1.00 | EEF2K (0.47) | EEF2KGAAKMT2AMEN1CNR2 | |
| SCHEMBL29115978 | 0.86 | CES2 (0.46) | EEF2KKMT2AMEN1CES2CES1 | |
| SCHEMBL29115980 | 0.86 | CES2 (0.46) | EEF2KKMT2AMEN1CES2CES1 | |
| SCHEMBL27504078 | 0.85 | GAA (0.46) | EEF2KGAAKMT2AMEN1CNR2 | |
| SCHEMBL5685248 | 0.82 | EEF2K (0.50) | EEF2KGAAKMT2AMEN1CNR2 | |
| SCHEMBL23217529 | 0.82 | GAA (0.44) | EEF2KGAAKMT2AMEN1CNR2 | |
| SCHEMBL19143602 | 0.81 | IDO1 (0.40) | EEF2KGAAKMT2AMEN1CNR2 | |
| SCHEMBL20545648 | 0.80 | FFAR1 (0.51) | EEF2KGAACTSA | |
| SCHEMBL20545647 | 0.80 | FFAR1 (0.51) | EEF2KGAACTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-20200216836-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20190330618-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2019-10-31 | — | — | US | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| US-10287576-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2019-05-14 | — | — | US | disclosed |
| CN-105377851-B | BET bromodomain inhibitors and therapeutic methods using these inhibitors | 密执安州立大学董事会 | 2018-07-20 | — | — | CN | disclosed |
| EP-3305900-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2018-04-11 | — | — | EP | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-1957644-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20100285540-A1 | Process for the preparation of (R)-Beta-Arylalanines by coupled Racemase/Aminomutase catalysis | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100285540-A1 | Process for the preparation of (R)-Beta-Arylalanines by coupled Racemase/Aminomutase catalysis | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-11-11 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | UBE INDUSTRIES, LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2000071572-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | EEF2K 1891/4885GAA 176/4885KMT2A 1082/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | EEF2K 714/4885GAA 1549/4885KMT2A 337/4885 |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | ALAD, ARSA, ALDH7A1 | EEF2K 1880/4885GAA 2136/4885KMT2A 4127/4885 |
| US-20100285540-A1 | Process for the preparation of (R)-Beta-Arylalanines by coupled Racemase/Aminomutase catalysis | ARSA, RNPEP, DDC | EEF2K 2453/4885GAA 217/4885KMT2A 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.